WASHINGTON – The U.S. Food and Drug Administration revised the emergency use authorization for Paxlovid, nirmatrelvir and ritonavir, to authorize state-licensed pharmacists to prescribe Paxlovid to eligible patients, with certain limitations to ensure appropriate patient assessment and prescribing of Paxlovid Wednesday, July 6.“The FDA recognizes the important role pharmacists have played and continue to play in combating this pandemic,” Dr. Patrizia Cavazzoni, director for the FDA’s Center for Drug Evaluation and Research, said. “Since Paxlovid must be taken within five days after symptoms begin, authorizing state-licensed pharmacists to prescribe Paxlovid could expand access to timely treatment for some patients who are eligible to receive this drug for the treatment of CO
